Shares of Wave Life Sciences Ltd (NASDAQ:WVE) have been given an average recommendation of “Buy” by the eleven brokerages that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $22.75.
WVE has been the subject of a number of research reports. ValuEngine lowered Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, December 16th. BidaskClub raised Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, December 4th. Svb Leerink lowered Wave Life Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $33.00 to $10.00 in a research note on Tuesday, December 31st. HC Wainwright decreased their price target on Wave Life Sciences from $33.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, January 2nd. Finally, Mizuho initiated coverage on Wave Life Sciences in a research note on Monday, December 30th. They set a “buy” rating and a $65.00 price target for the company.
In other news, Director Gregory L. Verdine sold 30,039 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $30.63, for a total value of $920,094.57. Following the completion of the sale, the director now owns 36,009 shares in the company, valued at $1,102,955.67. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Chandra Vargeese sold 6,000 shares of the stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $32.34, for a total value of $194,040.00. 39.70% of the stock is owned by corporate insiders.
WVE stock traded up $0.11 on Friday, reaching $8.07. The company’s stock had a trading volume of 303,983 shares. Wave Life Sciences has a 52 week low of $6.89 and a 52 week high of $48.64. The firm has a fifty day moving average of $8.27 and a two-hundred day moving average of $20.01.
Wave Life Sciences Company Profile
Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Further Reading: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.